MCID: ALL006
MIFTS: 54

Allergic Asthma

Categories: Respiratory diseases, Immune diseases

Aliases & Classifications for Allergic Asthma

MalaCards integrated aliases for Allergic Asthma:

Name: Allergic Asthma 12 25 14 69
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Ige-Mediated Allergic Asthma 69
Extrinsic Asthma 25
Asthma Allergic 52
Atopic Asthma 12

Classifications:



Summaries for Allergic Asthma

Genetics Home Reference : 25 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder.

MalaCards based summary : Allergic Asthma, also known as extrinsic asthma with acute exacerbation, is related to rheumatoid arthritis and asthma. An important gene associated with Allergic Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Capsaicin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
id Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 29.5 CCL5 IFNG IL10 IL17A IL4
2 asthma 25.1 ADAM33 CCL11 CCL17 CCL5 EPX GATA3
3 atopy 11.2
4 myoclonic astatic epilepsy 10.9 IFNG IL4
5 cytoplasmic body myopathy 10.9 IL13 IL5
6 aspergillosis 10.9
7 acute ackee fruit intoxication 10.8 IL10 IL4
8 gastroschisis 10.8 IFNG IL5
9 abdominal tuberculosis 10.8 IL13 IL4 IL5
10 marasmus 10.8 IL4 IL5 RNASE3
11 glucose intolerance 10.8 IL13 IL4 IL5
12 orbital plasma cell granuloma 10.8 IL4 IL5 RNASE3
13 papillary follicular thyroid adenocarcinoma 10.8 IL5 RNASE3
14 anterior dislocation of lens 10.8 CCL11 IL4 RNASE3
15 aortic arch interruption 10.8 IL13 IL5
16 hypothyroidism due to deficient transcription factors involved in pituitary development or function 10.8 IFNG IL4 IL5
17 cystadenocarcinoma 10.8 IL10 IL13
18 hypercementosis 10.8 CCL5 IL13 IL5
19 eye accommodation disease 10.8 IFNG IL10 IL4
20 penis agenesis 10.8 CCL11 IL5
21 thelaziasis 10.8 IFNG IL10 IL4
22 indian tick typhus 10.8 CCL5 IFNG IL13
23 hypercalcinuria macular coloboma 10.8 IFNG IL4 IL4R
24 crustacean allergy 10.7 IL10 IL5 RNASE3
25 centronuclear myopathy 5 10.7 IFNG IL10 IL4
26 papillary squamous carcinoma 10.7 IFNG IL10 IL13
27 skin disease 10.7 IL4R IL5 RNASE3
28 spindle cell hemangioma 10.7 IFNG IL10 IL4
29 exophthalmos 10.7 CCL5 IL5 RNASE3
30 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.7 IFNG IL10 IL5
31 tularemia 10.7 IFNG IL10 IL4
32 early-onset zonular cataract 10.7 IFNG IL10 IL4
33 frontal sinus schneiderian papilloma 10.7 IL13 IL5 TSLP
34 acute monoblastic leukemia 10.7 IFNG IL10 IL4
35 hidradenitis suppurativa 10.7 CCL11 CCL5 IL10
36 middle lobe syndrome 10.7 IFNG IL13 IL4
37 vascular dementia 10.7 CCL5 IL10 IL4
38 purpura fulminans 10.7 IL13 IL4 IL5 RNASE3
39 nonspecific interstitial pneumonia 10.7 CCL17 IL10 IL5
40 malignant hyperthermia 10.7 IFNG IL4 IL5
41 esophagus melanoma 10.7 IFNG IL10 IL4
42 dioctophymiasis 10.7 CCL11 IL13 IL4 IL5
43 epididymis adenocarcinoma 10.7 CCL11 IL13 IL4 IL5
44 myofibroma 10.6 IL13 IL5 STAT6
45 fungal gastritis 10.6 CCL11 IL13 IL4 IL5
46 status epilepticus 10.6 CCL5 IFNG IL4
47 x-linked intellectual disability, van esch type 10.6 IFNG IL4 IL5 RNASE3
48 psychologic dyspareunia 10.6 CCL5 IFNG IL10
49 acute interstitial pneumonia 10.6 IFNG IL10 IL4
50 dysphagia 10.6 CCL5 IFNG IL10

Graphical network of the top 20 diseases related to Allergic Asthma:



Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma

MGI Mouse Phenotypes related to Allergic Asthma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CCL11 CCL17 CCL5 EPX GATA3 IFNG
2 immune system MP:0005387 10.21 IL10 IL13 IL16 IL17A IL4 IL4R
3 digestive/alimentary MP:0005381 10.06 GATA3 IFNG IL10 IL13 IL17A IL4
4 endocrine/exocrine gland MP:0005379 10.02 GATA3 IFNG IL10 IL13 IL17A IL4
5 integument MP:0010771 9.76 GATA3 IFNG IL10 IL13 IL4 IL4R
6 no phenotypic analysis MP:0003012 9.5 IFNG IL10 IL13 IL17A IL4 ADAM33
7 respiratory system MP:0005388 9.36 CCL11 IFNG IL10 IL13 IL17A IL4

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 242138-07-4
2
Capsaicin Approved Phase 4 404-86-4 1548943
3
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
4
Ephedrine Approved Phase 4,Phase 2,Phase 1 299-42-3 9294
5
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 75614-87-8, 51-45-6 774
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
8
Pseudoephedrine Approved Phase 4,Phase 2,Phase 1 90-82-4 7028
9
Xylometazoline Approved Phase 4 526-36-3 5709
10
Nitric Oxide Approved Phase 4,Phase 3,Phase 2 10102-43-9 145068
11
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1 158966-92-8 5281040
12
Ciclesonide Approved, Investigational Phase 4,Phase 2,Phase 1 126544-47-6, 141845-82-1 444033
13
Levocetirizine Approved Phase 4 130018-77-8
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Terbutaline Approved Phase 4 23031-25-6 5403
16
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
17
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
18
Theophylline Approved Phase 4,Phase 2 58-55-9 2153
19
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
20
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 63006 5281004
21
Cetirizine Approved Phase 4,Phase 1 83881-51-0 2678
22
Desloratadine Approved, Investigational Phase 4,Phase 2,Phase 3 100643-71-8 124087
23
Adenosine Approved, Investigational Phase 4 58-61-7 60961
24
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
25 Racepinephrine Approved Phase 4,Phase 3,Phase 2
26
Doxazosin Approved Phase 4 74191-85-8 3157
27
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
28
Metronidazole Approved Phase 4 443-48-1 4173
29
Vancomycin Approved Phase 4 1404-90-6 441141 14969
30
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
31
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
32 Anti-Allergic Agents Phase 4,Phase 2,Phase 3,Phase 1
33 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
35 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
36 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
37 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Antipruritics Phase 4,Phase 3,Phase 2,Phase 1
39 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
45 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
46 Histamine Antagonists Phase 4,Phase 2,Phase 3,Phase 1
47 Histamine H1 Antagonists Phase 4,Phase 2,Phase 3,Phase 1
48 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 2,Phase 3
49
Histamine Phosphate Phase 4,Phase 2,Phase 3,Phase 1 51-74-1 65513
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 587)

id Name Status NCT ID Phase Drugs
1 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
2 Predicting the Clinical Response to Omalizumab With Anti-IgE Ab Response or Syk Expression in Basophils Unknown status NCT02023151 Phase 4 Omalizumab;Placebo injection
3 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
4 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
5 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
6 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
7 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
8 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
9 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4 5 grass allergen extract
10 Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children Unknown status NCT00172341 Phase 4 Staloral TM
11 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
12 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4 Omalizumab;Placebo
13 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4 omalizumab at a dose of 0.016mg/kg/IU/mL;Placebo
14 Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
15 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
16 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed NCT00264849 Phase 4 Omalizumab
17 Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy Completed NCT00329381 Phase 4 Xolair;Xolair
18 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
19 Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Completed NCT00490425 Phase 4 Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
20 Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen Completed NCT00518518 Phase 4 Staloral 300;placebo
21 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
22 Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
23 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma Completed NCT00980707 Phase 4 Inhaled corticosteroid (fluticasone)
24 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
25 Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Completed NCT00492076 Phase 4
26 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed NCT01125748 Phase 4 Omalizumab;Placebo;Asthma therapies
27 Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
28 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed NCT00454051 Phase 4 Omalizumab;placebo
29 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
30 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
31 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
32 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
33 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
34 The Effect of Xolair (Omalizumab) on Allergy Blood Cells Completed NCT00657891 Phase 4 Omalizumab;Placebo
35 Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis Completed NCT01550471 Phase 4 Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo;Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase;QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo;QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris;Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase;Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
36 Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367) Completed NCT00442559 Phase 4 montelukast sodium;inhaled corticosteroid
37 Study of Bronchodilation Effects of Cetirizine Completed NCT01781507 Phase 4 Cetirizine;Placebo
38 Singulair(R) In Asthma And Allergic Rhinitis (0476-383) Completed NCT00545844 Phase 4 montelukast sodium
39 Study Of Patients With Allergic Rhinitis And Asthma Completed NCT00296530 Phase 4 fluticasone propionate/salmeterol;fluticasone propionate;montelukast
40 Study Of Allergic Rhinitis In Patients Who Also Have Asthma Completed NCT00296491 Phase 4 fluticasone propionate/salmeterol (FSC);montelukast (MON);fluticasone propionate (FP);placebo nasal;ADVAIR DISKUS;placebo capsule;placebo DISKUS
41 Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365) Completed NCT00380705 Phase 4 MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks
42 Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis Completed NCT00903227 Phase 4 Fluticasone Evohaler pMDI;Placebo;Fluticasone Evohaler;Placebo intranasal spray;fluticasone propionate (Flixonase®)
43 Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
44 Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen? Completed NCT00716963 Phase 4 Fluticasone propionate (Flovent Diskus) 250 mcg;budesonide 400 mcg
45 A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels Completed NCT00624832 Phase 4 Xolair;Placebo
46 Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge Completed NCT01657097 Phase 4 INCS;Placebo
47 Anti-inflammatory H1 Antihistamines Allergic Rhinitis Completed NCT02507635 Phase 4 Levocetirizine;Desloratadine
48 A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329) Completed NCT00157937 Phase 4 MK0476; montelukast sodium/Duration of Treatment: 16 weeks;Comparator: theophylline ER/Duration of Treatment: 16 weeks
49 A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy Completed NCT00250263 Phase 4 (agent for immunotherapy) Staloral;Placebo
50 Effects of Montelukast in Asthmatic Children With and Without Food Allergy Completed NCT01618929 Phase 4 Montelukast

Search NIH Clinical Center for Allergic Asthma

Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

39
Lung, T Cells, Testes, Skin, Neutrophil, Bone, B Cells

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 804)
id Title Authors Year
1
Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma. ( 28867182 )
2017
2
Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. ( 28532191 )
2017
3
Response to omalizumab in patients with severe allergic asthma: A real-life study. ( 28947015 )
2017
4
Concomitant suppression of Th2 and Th17 cell responses in allergic asthma by targeting RORI^t. ( 28943467 )
2017
5
Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma. ( 28063043 )
2017
6
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. ( 28838980 )
2017
7
The C5a/C5aR1 axis controls the development of experimental allergic asthma independent of LysM-expressing pulmonary immune cells. ( 28931049 )
2017
8
Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. ( 28936430 )
2017
9
Differential regulation of PD-1 and its ligands in allergic asthma. ( 28865147 )
2017
10
Chlamydia pneumoniae Induces Interferon Gamma Responses in Peripheral Blood Mononuclear Cells in Children with Allergic Asthma. ( 28480606 )
2017
11
Effect of polymorphisms on TGFB1 on allergic asthma and helminth infection in an African admixed population. ( 28284979 )
2017
12
Maternal Exposure of BALB/c Mice to Indoor NO2 and Allergic Asthma Syndrome in Offspring at Adulthood with Evaluation of DNA Methylation Associated Th2 Polarization. ( 28935613 )
2017
13
Th9 and other IL-9-producing cells in allergic asthma. ( 27858144 )
2017
14
Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation. ( 28920926 )
2017
15
Bupleurum chinense extract ameliorates an OVA-induced murine allergic asthma through the reduction of the Th2 and Th17 cytokines production by inactivation of NFI_B pathway. ( 28531919 )
2017
16
TLR 7/8 Ligand, S28463, Suppresses Ascaris Suum Induced Allergic Asthma in Nonhuman Primates. ( 28850259 )
2017
17
Inhibitory effects of l-theanine on airway inflammation in ovalbumin-induced allergic asthma. ( 27908701 )
2017
18
Systemic and mucosal pre-administration of recombinant Helicobacter pylori neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice. ( 28087613 )
2017
19
LAT alleviates Th2/Treg imbalance in an OVA-induced allergic asthma mouse model through LAT-PLC-I^1 interaction. ( 28063403 )
2017
20
Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models. ( 28835901 )
2017
21
Propofol inhibits NF-I_B activation to ameliorate airway inflammation in ovalbumin (OVA)-induced allergic asthma mice. ( 28843179 )
2017
22
Murine Models of Allergic Asthma. ( 28063042 )
2017
23
The Effect of Zataria multiflora on Th1/Th2 and Th17/T Regulatory in a Mouse Model of Allergic Asthma. ( 28824424 )
2017
24
Role of PIM2 in allergic asthma. ( 28944837 )
2017
25
Ameliorative effects of Artemisia pallens in a murine model of ovalbumin-induced allergic asthma via modulation of biochemical perturbations. ( 28810518 )
2017
26
Omalizumab in non-allergic Asthma: A report of 13 cases. ( 28800272 )
2017
27
The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. ( 28859150 )
2017
28
ERJ August Podcast: Fevipiprant in allergic asthma not controlled by low-dose inhaled corticosteroids. ( 28838974 )
2017
29
Trigonella foenum-graecum alleviates airway inflammation of allergic asthma in ovalbumin-induced mouse model. ( 27939889 )
2017
30
Increased expression of nuclear factor of activated TA cells 1 drives IL-9-mediated allergic asthma. ( 26993036 )
2016
31
Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children. ( 27831636 )
2016
32
Women using bleach for home cleaning are at increased risk of non-allergic asthma. ( 27492540 )
2016
33
Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma. ( 28066430 )
2016
34
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. ( 27377155 )
2016
35
P2Y6 contributes to ovalbumin-induced allergic asthma by enhancing mast cell function in mice. ( 27590515 )
2016
36
Regulation and function of anaphylatoxins and their receptors in allergic asthma. ( 27916272 )
2016
37
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. ( 27117315 )
2016
38
IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma. ( 26762527 )
2016
39
Origin, Localization, and Immunoregulatory Properties of Pulmonary Phagocytes in Allergic Asthma. ( 27047494 )
2016
40
Allergic Asthma: A summary from genetic basis, mouse studies, to diagnosis and treatment. ( 27573930 )
2016
41
Comorbidity in allergic asthma and allergic rhinitis: functional somatic syndromes. ( 28034321 )
2016
42
Regular and moderate aerobic training before allergic asthma induction reduces lung inflammation and remodeling. ( 27152850 )
2016
43
Molecular engineering of a therapeutic antibody for Blo t 5-induced allergic asthma. ( 27923562 )
2016
44
Rosae Multiflorae Fructus Hot Water Extract Inhibits a Murine Allergic Asthma Via the Suppression of Th2 Cytokine Production and Histamine Release from Mast Cells. ( 27574849 )
2016
45
Behavioral impact of maternal allergic-asthma in two genetically distinct mouse strains. ( 27622677 )
2016
46
Cost utility analysis of the SQ(Ar) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. ( 27610217 )
2016
47
Challenges in the management of severe allergic asthma in the elderly. ( 27051308 )
2016
48
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. ( 27354118 )
2016
49
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma. ( 27656673 )
2016
50
ADRB2 polymorphisms in allergic asthma in Han Chinese children. ( 26633084 )
2016

Variations for Allergic Asthma

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CCL11 CCL5 EPX GATA3 IFNG IL10
2
Show member pathways
13.87 CCL11 CCL17 CCL5 IL10 IL13 IL16
3
Show member pathways
13.73 CCL11 CCL17 CCL5 IFNG IL10 IL13
4
Show member pathways
13.62 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Show member pathways
13.47 CCL11 CCL17 CCL5 IL10 IL13 IL16
6
Show member pathways
13.41 CCL11 CCL5 GATA3 IFNG IL10 IL13
7
Show member pathways
13.39 CCL11 CCL17 CCL5 IL10 IL13 IL16
8
Show member pathways
12.87 CCL11 EPX IFNG IL10 IL13 IL17A
9
Show member pathways
12.68 IFNG IL10 IL4 IL4R ITK MS4A2
10
Show member pathways
12.65 GATA3 IFNG IL10 IL13 IL17A IL4
11 12.63 CCL5 GATA3 IFNG IL10 IL17A IL4
12
Show member pathways
12.6 IL13 IL4 IL5 ITK MS4A2
13
Show member pathways
12.55 GATA3 IFNG IL10 IL17A IL4 IL5
14
Show member pathways
12.44 CCL11 CCL17 IFNG IL13 IL17A IL4
15
Show member pathways
12.43 CCL11 GATA3 IL4 IL4R STAT6
16
Show member pathways
12.24 IFNG IL10 IL13 IL4 IL4R IL5
17
Show member pathways
12.23 IFNG IL10 IL13 IL16 IL17A IL4
18 12.03 IFNG IL10 IL4 IL5
19
Show member pathways
11.99 GATA3 IFNG IL10 IL17A
20 11.98 CCL11 GATA3 IL10 IL13 IL17A IL4
21
Show member pathways
11.96 IFNG IL17A IL4 IL4R
22 11.92 GATA3 IFNG IL13 IL4 IL5
23 11.91 IFNG IL10 IL4R STAT6
24 11.84 IL4 IL4R IL5
25
Show member pathways
11.82 GATA3 IFNG IL4 IL5
26 11.81 CCL5 IFNG IL17A
27 11.8 CCL11 CCL5 IL13 IL4 IL5
28 11.74 GATA3 IL10 IL5
29 11.71 CCL11 CCL17 IL10 IL4 IL4R IL5
30 11.69 IL10 IL4 IL5
31 11.66 GATA3 IFNG IL10 IL13 IL17A IL4
32 11.62 CCL5 IL10 IL13 IL4
33 11.45 IFNG IL4 IL4R IL5
34 11.39 IFNG IL10 IL13 IL4 IL5
35 11.31 IFNG IL10 IL13 IL4 IL5
36 11.21 GATA3 IL4 IL4R STAT6
37 11.14 CCL11 CCL17 CCL5 IL10 IL13 IL16
38 11.03 IL13 IL4 IL4R IL5
39 11 GATA3 IFNG IL13 IL17A IL4 IL5
40 10.99 CCL11 CCL17 GATA3 IFNG IL10 IL13

GO Terms for Allergic Asthma

Cellular components related to Allergic Asthma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CCL11 CCL17 CCL5 EPX IFNG IL10
2 external side of plasma membrane GO:0009897 9.55 IFNG IL13 IL17A IL4 MS4A2
3 extracellular space GO:0005615 9.47 CCL11 CCL17 CCL5 EPX IFNG IL10

Biological processes related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.97 CCL17 CCL5 IL10 IL13 IL17A
2 cellular response to tumor necrosis factor GO:0071356 9.87 CCL11 CCL17 CCL5 GATA3
3 response to virus GO:0009615 9.84 CCL11 CCL5 GATA3 IFNG
4 chemokine-mediated signaling pathway GO:0070098 9.83 CCL11 CCL17 CCL5
5 chemotaxis GO:0006935 9.83 CCL11 CCL17 CCL5 IL16 IL4
6 positive regulation of T cell proliferation GO:0042102 9.82 CCL5 IFNG IL4
7 response to cytokine GO:0034097 9.81 CCL5 IL4 STAT6
8 cellular response to interferon-gamma GO:0071346 9.81 CCL11 CCL17 CCL5
9 cellular response to interleukin-1 GO:0071347 9.81 CCL11 CCL17 CCL5 IL17A
10 monocyte chemotaxis GO:0002548 9.79 CCL11 CCL17 CCL5
11 positive regulation of B cell proliferation GO:0030890 9.79 IL13 IL4 IL5
12 neutrophil chemotaxis GO:0030593 9.78 CCL11 CCL17 CCL5 IFNG
13 microglial cell activation GO:0001774 9.67 IL13 IL4
14 leukocyte chemotaxis GO:0030595 9.67 IL10 IL16
15 positive regulation of macrophage activation GO:0043032 9.67 IL10 IL13 IL4R
16 positive regulation of isotype switching to IgG isotypes GO:0048304 9.66 IFNG IL4
17 positive regulation of chemokine biosynthetic process GO:0045080 9.66 IFNG IL4
18 eosinophil chemotaxis GO:0048245 9.65 CCL11 CCL5
19 positive regulation of interleukin-13 production GO:0032736 9.64 GATA3 IL4
20 type 2 immune response GO:0042092 9.63 IL10 IL4
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 CCL5 IFNG IL4
22 positive regulation of interleukin-23 production GO:0032747 9.62 IFNG IL17A
23 interleukin-4-mediated signaling pathway GO:0035771 9.61 IL4R STAT6
24 regulation of isotype switching GO:0045191 9.6 IL10 IL4
25 regulation of proton transport GO:0010155 9.59 IL13 IL4
26 T-helper 2 cell differentiation GO:0045064 9.58 GATA3 IL4
27 positive regulation of mast cell degranulation GO:0043306 9.58 IL13 IL4 IL4R
28 positive regulation of isotype switching to IgE isotypes GO:0048295 9.56 IL4 STAT6
29 negative regulation of endothelial cell apoptotic process GO:2000352 9.56 GATA3 IL10 IL13 IL4
30 inflammatory response GO:0006954 9.56 CCL11 CCL17 CCL5 IL10 IL13 IL17A
31 negative regulation of complement-dependent cytotoxicity GO:1903660 9.55 IL13 IL4
32 positive regulation of immunoglobulin production GO:0002639 9.54 IL13 IL4 IL4R
33 T-helper 1 cell lineage commitment GO:0002296 9.52 IL4 STAT6
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.5 IFNG IL10 IL4
35 defense response to protozoan GO:0042832 9.46 IFNG IL10 IL4 IL4R
36 immune response GO:0006955 9.4 CCL11 CCL17 CCL5 IFNG IL10 IL13

Molecular functions related to Allergic Asthma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 CCL11 CCL17 CCL5 IFNG IL10 IL13
2 chemokine activity GO:0008009 9.33 CCL11 CCL17 CCL5
3 CCR4 chemokine receptor binding GO:0031729 8.96 CCL17 CCL5

Sources for Allergic Asthma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....